CR20130671A - Antagonistas de trpv4 - Google Patents

Antagonistas de trpv4

Info

Publication number
CR20130671A
CR20130671A CR20130671A CR20130671A CR20130671A CR 20130671 A CR20130671 A CR 20130671A CR 20130671 A CR20130671 A CR 20130671A CR 20130671 A CR20130671 A CR 20130671A CR 20130671 A CR20130671 A CR 20130671A
Authority
CR
Costa Rica
Prior art keywords
trpv4 antagonists
trpv4
antagonists
pharmaceutical compositions
relates
Prior art date
Application number
CR20130671A
Other languages
English (en)
Inventor
Carl Brooks
Mui Cheung
Hilary Schenck Eidam
Krista B Goodman
Marlys Hammond
Mark A Hilfiker
Tram H Hoang
Jaclyn R Patterson
Patrick Stoy
Guosen Ye
Original Assignee
Glaxosmithkline Intellectual Property (No.2) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47558389&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130671(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property (No.2) Limited filed Critical Glaxosmithkline Intellectual Property (No.2) Limited
Publication of CR20130671A publication Critical patent/CR20130671A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

La presente invención se refiere a análogos de espirocarbamato, a composiciones farmacéuticas que los contienen y a su uso como antagonistas de 5 TRPV4.
CR20130671A 2011-06-17 2013-12-17 Antagonistas de trpv4 CR20130671A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161498110P 2011-06-17 2011-06-17

Publications (1)

Publication Number Publication Date
CR20130671A true CR20130671A (es) 2014-02-04

Family

ID=47558389

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130671A CR20130671A (es) 2011-06-17 2013-12-17 Antagonistas de trpv4

Country Status (38)

Country Link
US (1) US9187464B2 (es)
EP (2) EP3121177B1 (es)
JP (1) JP5969017B2 (es)
KR (1) KR101870003B1 (es)
CN (1) CN103732583B (es)
AR (1) AR086958A1 (es)
AU (1) AU2012284540B2 (es)
BR (1) BR112013032391B1 (es)
CA (1) CA2839743C (es)
CL (1) CL2013003602A1 (es)
CO (1) CO6821953A2 (es)
CR (1) CR20130671A (es)
CY (1) CY1117792T1 (es)
DK (1) DK2721016T3 (es)
DO (1) DOP2013000307A (es)
EA (1) EA023616B1 (es)
ES (2) ES2569193T3 (es)
HK (1) HK1195068A1 (es)
HR (1) HRP20160539T1 (es)
HU (1) HUE029594T2 (es)
IL (1) IL229872A (es)
JO (1) JO3154B1 (es)
MA (1) MA35184B1 (es)
ME (1) ME02416B (es)
MX (1) MX337440B (es)
MY (1) MY173521A (es)
PE (1) PE20141943A1 (es)
PL (1) PL2721016T3 (es)
PT (1) PT2721016E (es)
RS (1) RS54858B1 (es)
SG (1) SG195106A1 (es)
SI (1) SI2721016T1 (es)
SM (1) SMT201600150B (es)
TW (1) TWI538912B (es)
UA (1) UA113963C2 (es)
UY (1) UY34138A (es)
WO (1) WO2013012500A1 (es)
ZA (1) ZA201308816B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487507B2 (en) 2011-06-17 2016-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited TRPV4 antagonists
JP5969015B2 (ja) 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
JPWO2015046193A1 (ja) 2013-09-25 2017-03-09 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
WO2017199199A1 (en) 2016-05-19 2017-11-23 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonist
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
WO2018185701A1 (en) 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
EA202091101A1 (ru) * 2017-11-01 2020-08-06 Бристол-Маерс Сквибб Компани Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора
WO2021170811A1 (en) 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Method of treating eye disease using trpv4 antagonists
WO2021221169A1 (en) 2020-04-30 2021-11-04 Raqualia Pharma Inc. Pyrimidin-4(3h)-one derivatives as trpv4 antagonists
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
MX2023000610A (es) 2020-07-16 2023-02-13 Raqualia Pharma Inc Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
WO2024011214A1 (en) 2022-07-08 2024-01-11 Actio Biosciences, Inc. Therapeutic compounds and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482945T1 (de) * 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
AU2004257289A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
CN101346375B (zh) * 2005-11-23 2013-04-10 阿罗斯药物有限责任公司 调节门离子通道用组合物和方法
WO2007067756A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
TWI423819B (zh) * 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
TW200838508A (en) * 2007-02-01 2008-10-01 Glaxo Group Ltd Chemical compounds
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
JP2010535812A (ja) * 2007-08-09 2010-11-25 アボット・ラボラトリーズ Ｔｒｐｖ１拮抗薬としてのテトラヒドロピリジンカルボキサミド誘導体
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
JP5607046B2 (ja) * 2008-07-25 2014-10-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｔｒｐｖ４拮抗薬
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体
WO2012024183A1 (en) * 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US9487507B2 (en) * 2011-06-17 2016-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited TRPV4 antagonists
JP5969015B2 (ja) * 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬

Also Published As

Publication number Publication date
BR112013032391A2 (pt) 2016-08-16
PE20141943A1 (es) 2014-12-28
CY1117792T1 (el) 2017-05-17
ES2688733T3 (es) 2018-11-06
BR112013032391B1 (pt) 2020-11-24
HK1195068A1 (zh) 2014-10-31
AU2012284540A1 (en) 2013-04-04
DK2721016T3 (en) 2016-06-06
EP2721016A4 (en) 2014-10-08
US9187464B2 (en) 2015-11-17
PT2721016E (pt) 2016-06-06
CN103732583A (zh) 2014-04-16
JO3154B1 (ar) 2017-09-20
CA2839743A1 (en) 2013-01-24
HRP20160539T1 (hr) 2016-06-17
AU2012284540B2 (en) 2014-08-28
CA2839743C (en) 2017-03-28
PL2721016T3 (pl) 2017-01-31
ES2569193T3 (es) 2016-05-09
MX2013014898A (es) 2014-03-21
UY34138A (es) 2013-01-03
AR086958A1 (es) 2014-02-05
SI2721016T1 (sl) 2016-06-30
IL229872A (en) 2017-03-30
TWI538912B (zh) 2016-06-21
JP2014518214A (ja) 2014-07-28
WO2013012500A1 (en) 2013-01-24
EP3121177A1 (en) 2017-01-25
ME02416B (me) 2016-09-20
SG195106A1 (en) 2013-12-30
EA023616B1 (ru) 2016-06-30
RS54858B1 (sr) 2016-10-31
MA35184B1 (fr) 2014-06-02
MY173521A (en) 2020-01-30
CO6821953A2 (es) 2013-12-31
EA201490037A1 (ru) 2015-12-30
JP5969017B2 (ja) 2016-08-10
UA113963C2 (xx) 2017-04-10
EP2721016A1 (en) 2014-04-23
MX337440B (es) 2016-03-03
EP3121177B1 (en) 2018-08-01
SMT201600150B (it) 2016-07-01
DOP2013000307A (es) 2014-06-01
KR101870003B1 (ko) 2018-06-22
TW201313705A (zh) 2013-04-01
NZ618221A (en) 2015-02-27
CL2013003602A1 (es) 2014-07-04
US20140121206A1 (en) 2014-05-01
KR20140041733A (ko) 2014-04-04
CN103732583B (zh) 2015-12-23
ZA201308816B (en) 2015-02-25
HUE029594T2 (en) 2017-03-28
EP2721016B1 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
CR20130671A (es) Antagonistas de trpv4
DOP2016000145A (es) Reguladores de nrf2
DOP2017000298A (es) Reguladores de nrf2
UY37410A (es) Antagonistas de trpv4
CR20150370A (es) Compuestos antivirales
ECSP15022555A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP13013074A (es) Nuevos derivados de piridina
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP11011517A (es) Compuestos antivirales
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
PE20171444A1 (es) Compuestos antivirales
UY33735A (es) Compuestos antivirales
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP14013327A (es) Compuestos con actividad nematicida
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20150250A (es) Nuevos derivados de piridina
CR20150204A (es) Nuevos derivados de piridina
CR20120542A (es) HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS
NI201500050A (es) Benzamidas
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
BR112019005416A2 (pt) antagonistas de trpv4
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina